NIH Clinical Research Studies

Protocol Number: 04-EI-0157

Active Accrual, Protocols Recruiting New Patients

Title:
Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31]
Number:
04-EI-0157
Summary:
This study will evaluate patients with eye complications related to vaccination against smallpox to learn more about these conditions. Vaccinia vaccination has been used for more than 100 years for preventing smallpox. A small number of people who receive the vaccination (less than 1 in 1,000) develop complications, sometimes in their eyes. This usually results from the accidental transfer of the infection from the vaccination site to the face or eyes, perhaps by touching the vaccination area and then the face or eyelids before washing the hands. The study will also examine whether an experimental treatment called NP-016 vaccinia immune globulin can reduce corneal scarring that is sometimes associated with serious vaccinia complications and can impair vision.

Children and adults with keratitis, severe conjunctivitis, or blepharitis following exposure to vaccinia vaccination may be eligible for this study. Children must weigh at least 10 kg.

Participants undergo the following tests and procedures at enrollment, with some tests repeated at scheduled study visits:

1) Medical history and physical examination

2) Infectious disease consultation

3) Complete eye evaluation including:

- Fundus photography to examine the back of the eye - dilation of the pupils with eye drops to examine and photograph the back of the eye

- Slit lamp biomicroscopy - evaluation of the front part of the eye with a slit lamp microscope

- Eye pressure measurements

- Eye swab to look for vaccinia virus or other causes of disease

4) Blood tests

5) Photographs and documentation of eye and skin lesions

6) Vaccinia diagnostic tests, such as skin or mucosa scrapings; blood, throat, or urine cultures; and tissue biopsies, if needed

Patients begin treatment with standard medications for their eye disease, such as trifluridine (Viroptic® (Registered Trademark)) anti-viral eye drops. Patients whose condition becomes serious are offered additional treatment with intravenous (through a vein) infusions of either VIG or placebo (salt water solution with no active drug) and are randomly assigned to one or the other treatment group. All patients continue standard-of-care treatment as well.

Follow-up visits at the NIH eye clinic are scheduled as required by the patient's condition. Patients with mild complications who are taking only standard medications may need to be seen only 1 month after the initial visit and then 6 months and 12 months later. Patients with more serious conditions who qualify for VIG or placebo treatments may be seen daily for a week, then once a week for the rest of the first month, and then at 6 months and 12 months, unless more frequent treatment or observation is required.

Sponsoring Institute:
National Eye Institute (NEI)
Recruitment Detail
Type: Active Accrual Of New Subjects
Gender: Male & Female
Referral Letter Required: No
Population Exclusion(s): None

Eligibility Criteria:
INCLUSION CRITERIA:

To be eligible to enroll in this study, a prospective participant must satisfy all of the following inclusion criteria:

1. The participant, or their parent or guardian if younger than 18 years at enrollment, is able to understand and sign an approved consent form. Any minor participant with adequate reading and writing skills must also sign an assent using a form approved by the local Institutional Review Board or Independent Ethics Committee (IRB/IEC). Minors with verbal skills but without adequate reading and writing skills should have an acknowledgement signed by their parent or guardian to certify that verbal assent to participate was obtained.

2. The participant must have received the vaccinia vaccination, been exposed to a person vaccinated with vaccinia who has skin lesions, or been exposed directly to accidental splash of the vaccine.

3. Have signs and symptoms consistent with ocular vaccinia.

4. To be eligible for randomization at the time of enrollment (or at any time during the study if the participant was not randomized at enrollment) the participant must have ocular features consistent with of any one or more of the following:

Keratitis- corneal ulcer, stromal haze or infiltrate at any level of severity.

Severe Conjunctivitis- at least one of these: membrane, ulceration/epithelial breakdown, focal lesion.

Mild or Severe Blepharitis- pustules involving at least 1/3 of lid margin, edema and hyperemia.

EXCLUSION CRITERIA:

To be randomized to the VIG/placebo treatment, a proposed participant must not satisfy the following exclusion criteria:

1. Children with body weight less than 10 kg.

2. Have a known severe reaction to the IV or IM administration of human immunoglobulin.

3. Have a known IgA deficiency or other immune deficiency.

4. Have known severe acute allergic reactions to the non-active ingredients of polysorbate 80, maltose, or the trace amounts of TNBP or Triton X-100 used in the preparation of VIG.

5. Is already receiving VIG.

6. Pregnant women, unless an approved, specific additional consent statement attesting to awareness of the unknown risk of VIG therapy during pregnancy is understood and signed by the participant.

7. Have orbital cellulites.

Special Instructions: Currently Not Provided
Keywords:
Smallpox
Cowpox
Corneal Ulcer
Keratitis
Immune Response, Vaccine
Recruitment Keywords:
Conjunctivitis
Keratitis
Corneal Ulcer
Vaccinia Vaccination
Smallpox Vaccination
Conditions:
Vaccinia
Investigational Drug(s):
NP-016 VIG
Investigational Device(s):
None

Contacts:
Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:
Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys.

J Infect Dis. 1970 Oct;122(4):303-9. No abstract available.

PMID: 4396189

Hyndiuk RA, Okumoto M, Damiano RA, Valenton M, Smolin G.

Treatment of vaccinial keratitis with vidarabine. Arch Ophthalmol. 1976 Aug;94(8):1363-4. PMID: 949279

Ruben FL, Lane JM. , Links Ocular vaccinia. An epidemiologic analysis of 348 cases. Arch Ophthalmol. 1970 Jul;84(1):45-8. No abstract available. PMID: 5423606

Active Accrual, Protocols Recruiting New Patients

If you have:


Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home


Clinical Center LogoWarren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/23/2004

Search The Studies Help Questions